Related references
Note: Only part of the references are listed.EGFR Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
Lynette M. Sholl et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
R. L. Rego et al.
BRITISH JOURNAL OF CANCER (2010)
Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma
Josh Sommer et al.
JOURNAL OF PATHOLOGY (2010)
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells
Li Lin et al.
MOLECULAR CANCER (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas†
Elena Tamborini et al.
NEURO-ONCOLOGY (2010)
Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib
Ola Linden et al.
ACTA ONCOLOGICA (2009)
Molecularly Targeted Therapies for Glioma
Ryuya Yamanaka et al.
ANNALS OF NEUROLOGY (2009)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
Response to erlotinib in a patient with treatment refractory chordoma
Nimit Singhal et al.
ANTI-CANCER DRUGS (2009)
Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
N. Presneau et al.
BRITISH JOURNAL OF CANCER (2009)
PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L. Sos et al.
CANCER RESEARCH (2009)
Aberrant Hyperactivation of Akt and Mammalian Target of Rapamycin Complex 1 Signaling in Sporadic Chordomas
Sangyeul Han et al.
CLINICAL CANCER RESEARCH (2009)
mTOR signaling at a glance
Mathieu Laplante et al.
JOURNAL OF CELL SCIENCE (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology
V. Martin et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer
M. Varella-Garcia et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors
Yoh Dobashi et al.
MODERN PATHOLOGY (2009)
Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas
Asem A. E. Shalaby et al.
MODERN PATHOLOGY (2009)
A novel target for treatment of chordoma: signal transducers and activators of transcription 3
Cao Yang et al.
MOLECULAR CANCER THERAPEUTICS (2009)
PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor
Federica Perrone et al.
NEURO-ONCOLOGY (2009)
Brachyury expression in extra-axial skeletal and soft tissue chordomas: A marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue
Roberto Tirabosco et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas
David T. W. Jones et al.
CANCER RESEARCH (2008)
KRAS mutations predict response to EGFR inhibitors
Mitch Raponi et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry
Ferenc Pinter et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2008)
Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number
Antoine Italiano et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial
Karen G. Chee et al.
CLINICAL GENITOURINARY CANCER (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Pten inactivation and the emergence of androgen-independent prostate cancer
Michael M. Shen et al.
CANCER RESEARCH (2007)
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray
Frederic Bibeau et al.
VIRCHOWS ARCHIV (2006)
Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas
S. Vujovic et al.
JOURNAL OF PATHOLOGY (2006)
Preclinical analysis of the analinoquinazoline AG14781 a specific small molecule inhibitor of EGF receptor tyrosine kinase
AG Ellis et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma
Holger Hof et al.
ONKOLOGIE (2006)
Randomized phase II - study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer - PARC: study protocol [ISRCTN56652283]
R Krempien et al.
BMC CANCER (2005)
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
F Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors
T Kusaba et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth
FM Corvinus et al.
NEOPLASIA (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Signaling by target of rapamycin proteins in cell growth control
K Inoki et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2005)
The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth
A Shushan et al.
HUMAN REPRODUCTION (2004)
Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues:: Variation in staining intensity due to choice of fixative and storage time of tissue sections
D Atkins et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
S Chan
BRITISH JOURNAL OF CANCER (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CHI
S Scheil et al.
GENES CHROMOSOMES & CANCER (2001)
EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells
XF Zhu et al.
CANCER LETTERS (2001)
Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33
MJ Kelley et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Chordoma: incidence and survival patterns in the United States, 1973-1995
ML McMaster et al.
CANCER CAUSES & CONTROL (2001)
Share Paper
